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EDITORIAL
Evaluation of glomerular lesions in diabetes mellitus
In diabetic patients renal disease often evolves over and mesangium for clear separation of the diabetic glo-
meruli from those in nondiabetic rats, following prescientthe first two decades (at least in type 1 diabetes mellitus).
advice from D.C. Sterio, who later published seminalThe earliest changes [for example, increased albumin
work on determining cell numbers [6]. Extending theexcretion and glomerular basement membrane (GBM)
current observations in a murine type 2 model of diabeticwidening] precede a greater loss of albumin, rising blood
renal disease, the same immunohistochemical documen-pressure, and marked changes in glomerular architec-
tation of CSPG deposition after only a month or two ofture. The quantitative evaluation of the lesions of dia-
streptozotocin diabetes may greatly shorten the minimalbetic nephropathy in human and animal models has often
interval of six months we previously needed to demon-required the adoption of morphometric techniques [1, 2],
strate glomerular lesions in streptozotocin diabetic ratsmost of which demand substantial effort and, impor-
[5]. To sustain this supposition, one would need to com-tantly, time to await the development of lesions that may
plete morphometric measures at the electron micro-be distinguished by stereologic techniques. In this issue
scopic level in direct comparison with immunostainingof Kidney International [3] and as previously reported [4],
procedures. The principal causative factors for diabeticMcCarthy and colleagues have demonstrated accumula-
nephropathy relate directly (but not completely) to thetion of chondroitin sulfate proteoglycan (CSPG) in the
level of glycemic control, as has been well demonstratedglomerulus very early in the course of renal disease in
in humans by the Diabetes Control and Complicationsmurine models of type 1 and type 2 diabetes mellitus.
Trial (DCCT, with type 1 diabetes) and the United King-In the current contribution, the renal lesions with diabe-
dom Prospective Diabetes Study (UKPDS, with type 2tes are marked, and the detection techniques of McCar-
diabetes) by measuring hemoglobin A1c [7, 8]. Alterna-thy et al captured the differences between diabetic and
tively, altered levels of lipids and lipid oxidation may be
nondiabetic animals. Other models of diabetic nephropa- important factors in the development of the micro- and
thy may not present such clear changes so quickly over the macrovascular complications of diabetes. McCarthy et al
course of disease; however, the observations of McCarthy studied troglitazone (a thiazolidinedione used to manage
et al [3, 4] may lead to more creative combinations of type 2 diabetes mellitus in humans and its effects on
immunohistochemical techniques and the principles of glycemic control, lipid levels and glomerular structure
morphometric analyses [1, 2] to provide quantitative and biochemistry [3]. In a balanced commentary on their
measures of diabetic glomerular disease. results the authors speculate whether troglitazone may
Since CSPG is a component of extracellular matrix, have exerted its beneficial effect through lipid biochemis-
its accumulation may relate directly to expansion of the try, in addition to restoring carbohydrate balance. Al-
mesangial matrix (as indicated in the current contribu- though additional work will be required to address this
tion). And significantly it may approximate the increase issue, glycemic factors seemed to be more readily nor-
in GBM width. In our response to the current and other malized, in contrast to the still somewhat abnormal lipid
articles by McCarthy et al, we reviewed nearly quarter- values in the diabetic rats receiving troglitazone.
century-old electron micrographs of diabetic rats [5], In addition to amelioration of the renal lesions in the
rat model of type 2 diabetes mellitus, McCarthy et al alsoan example shown here after 7 to 9 months of diabetes
documented striking preservation of architecture of the(Fig. 1). The less dense and loosely organized material
islets of Langerhans in those diabetic rats receiving trogli-on the endothelial aspect of the GBM comprised much
tazone, yielding a more appropriate (and diminished) se-of the increased thickness we determined by electron
cretion of insulin, which can act more effectively withmicroscopic morphometric procedures [5], and likely it
increased sensitivity engendered by troglitazone [3]. Thus,directly reflects an increase in deposition of CSPG by
the treated animals had nearly normal measurements ofthe methods of McCarthy and coworkers [3, 4]. In our
glycemia, likely due both to enhanced insulin action andexperiments, we waited 6 to 9 months following injection
the sustained capacity to secrete insulin from the appar-of streptozotocin to have sufficient changes in the GBM
ently normally functioning islets.
This article by McCarthy et al presents a successful
treatment to ameliorate the lesions of diabetic nephropa-Key words: renal injury, chondroitin sulfate proteoglycan, morphomet-
ric analysis, glycemia, insulin. thy in type 2 diabetes mellitus and with a new quantita-
tive approach to the measurement of glomerular archi-Ó 2000 by the International Society of Nephrology
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Fig. 1. An electron micrograph of the glomerular capillary wall of a rat diabetic for 7 to 9 months following streptozotocin. Note the widening
of the glomerular basement membrane (GBM), mostly caused by the presence of a poorly organized material on its endothelial aspect. An example
of biopsies measured in the late 1970s by Steffes et al [5].
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